Hope Biosciences' Stem Cell Therapy Achieves Primary Endpoint in Phase 2 Multiple Sclerosis Trial
Key Insights
Hope Biosciences (search)' autologous adipose-derived mesenchymal stem cell therapy met its primary endpoint, significantly improving quality of life measures in patients with relapsing-remitting multiple sclerosis (search) at 52 weeks.
The treatment demonstrated substantial improvements in both Physical Health Composite Score (22.12-point difference from placebo, P = .0002) and Mental Health Composite Score (15.76-point difference, P = .0166) on the MSQOL-54 assessment.
Secondary outcomes showed significant reductions in disability scores (EDSS) and depression scores (PHQ-9), with the therapy displaying a favorable safety profile and no severe treatment-related events.
Hope Biosciences (search)' autologous adipose-derived mesenchymal stem cell (HB-adMSC (search)) therapy has successfully met its primary endpoint in a phase 2 trial for relapsing-remitting multiple sclerosis (search) (RRMS (search)), demonstrating significant improvements in quality of life measures among patients. The late-breaking results, presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (search) (ECTRIMS) Congress in Barcelona, mark a potential breakthrough in stem cell therapy for autoimmune neurological conditions.
Trial Design and Patient Population
The phase 2, randomized, double-blind, placebo-controlled, single-center trial enrolled 24 patients with RRMS (search) between November 2021 and December 2024. Participants, aged 18 to 75 years with Expanded Disability Status Scale (EDSS) scores between 3.0 and 6.5, were randomized to receive either 200 million HB-adMSCs or placebo through six intravenous infusions administered at 0, 4, 8, 16, 24, and 32 weeks. Follow-up assessments were conducted at week 42, with the final evaluation at week 52.
Primary Endpoint Achievement
The study met its primary efficacy endpoint, showing statistically significant improvements in both components of the Multiple Sclerosis (search) Quality of Life-54 (MSQOL-54) instrument. Patients in the active treatment group demonstrated a least square mean change from baseline in Physical Health Composite Score (PHCS) of 19.87 (SE, 2.98), representing a 22.12-point difference from placebo (95% CI, 12.28-31.96; P = .0002; effect size, 1.23).
For the Mental Health Composite Score (MHCS), the treatment group showed a mean change of 13.36 (SE, 3.96), with a 15.76-point difference from placebo (95% CI, 3.31-28.22; P = .0166; effect size, 0.85). These improvements reflect meaningful enhancements in multiple dimensions of quality of life, including fatigue, physical and cognitive function, pain, energy, and mobility.
Secondary Outcomes and Safety Profile
Secondary outcomes strongly favored the HB-adMSC (search)-treated group, with patients demonstrating significant reductions in disability scores. The EDSS showed a -1.50 change from baseline, representing a -1.55 difference from placebo (95% CI, -2.91 to -0.19; P = .0278; effect size, 1.35). Depression scores, measured by PHQ-9, also improved significantly with a -4.33 change from baseline and a -4.59 difference from placebo (95% CI, -6.77 to -2.41; P = .0004; effect size, 0.84).
The treatment demonstrated a favorable safety profile throughout the study period. Adverse events were predominantly mild and transient, with no severe treatment-related events or deaths reported during the trial.
Clinical Significance and Expert Commentary
"The trial successfully met its primary endpoint, and the results clearly demonstrate that HB-adMSCs can be effective in a complex, variable condition like RRMS (search)," stated lead author Ridhima Vij, PhD, clinical research scientist and medical writer at Hope Biosciences Research Foundation (search). "There were statistically significant improvements in both physical and mental health for the treatment group compared to the placebo group as determined by the MS Quality of Life-54 Instrument."
Vij emphasized the comprehensive nature of the MSQOL-54 assessment, noting it captures multiple contributors to quality of life including fatigue, physical and cognitive function, sexual impairment, pain, energy, mobility, and level of disability. These factors are crucial considerations when evaluating how a therapeutic might revolutionize approaches to chronic degenerative diseases.
Regulatory Recognition and Future Directions
The promising results have garnered regulatory attention, with the FDA granting regenerative medicine advanced therapy designation for HB-adMSCs for treatment of patients with RRMS (search) in August 2025. This designation recognizes the therapy's potential to address unmet medical needs in multiple sclerosis (search) treatment.
"The results of this trial are groundbreaking for multiple sclerosis (search)," commented Donna Chang, president at Hope Biosciences Research Foundation (search). "They clearly demonstrate that high doses of fresh HB-adMSCs delivered on a regular schedule can result in consistent efficacy in a highly complex and variable condition like MS. We believe that this positive response will translate in other autoimmune diseases in the near future."
Research Implications
The study authors noted that while the current findings are encouraging, further research including larger and longer-term studies will be needed to evaluate the therapy's sustained efficacy and safety. The results suggest that autologous adipose-derived mesenchymal stem cell therapy represents a promising therapeutic approach for improving quality of life in patients with RRMS (search), potentially offering a new treatment paradigm for this challenging autoimmune condition.